CA2828478C - Serine/threonine kinase inhibitors - Google Patents

Serine/threonine kinase inhibitors Download PDF

Info

Publication number
CA2828478C
CA2828478C CA2828478A CA2828478A CA2828478C CA 2828478 C CA2828478 C CA 2828478C CA 2828478 A CA2828478 A CA 2828478A CA 2828478 A CA2828478 A CA 2828478A CA 2828478 C CA2828478 C CA 2828478C
Authority
CA
Canada
Prior art keywords
dihydro
pyrido
pyrimidine
alkyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2828478A
Other languages
English (en)
French (fr)
Other versions
CA2828478A1 (en
Inventor
James F. Blake
Huifen Chen
Mark Joseph Chicarelli
Jason DeMeese
Rustam Garrey
John J. Gaudino
Robert J. Kaus
Gabrielle R. Kolakowski
Allison L. Marlow
Peter J. Mohr
Li Ren
Jacob Schwarz
Christopher S. SIEDEM
Allen A. Thomas
Eli Wallace
Steven Mark Wenglowsky
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CA2828478A1 publication Critical patent/CA2828478A1/en
Application granted granted Critical
Publication of CA2828478C publication Critical patent/CA2828478C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2828478A 2011-02-28 2012-02-28 Serine/threonine kinase inhibitors Expired - Fee Related CA2828478C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161447587P 2011-02-28 2011-02-28
US61/447,587 2011-02-28
PCT/US2012/027009 WO2012118850A1 (en) 2011-02-28 2012-02-28 Serine/threonine kinase inhibitors

Publications (2)

Publication Number Publication Date
CA2828478A1 CA2828478A1 (en) 2012-09-07
CA2828478C true CA2828478C (en) 2019-12-31

Family

ID=45852719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2828478A Expired - Fee Related CA2828478C (en) 2011-02-28 2012-02-28 Serine/threonine kinase inhibitors

Country Status (11)

Country Link
US (1) US9133187B2 (enExample)
EP (1) EP2681215B1 (enExample)
JP (1) JP6085866B2 (enExample)
KR (1) KR101961500B1 (enExample)
CN (1) CN103635472B (enExample)
BR (1) BR112013021896A2 (enExample)
CA (1) CA2828478C (enExample)
ES (1) ES2543050T3 (enExample)
MX (1) MX339873B (enExample)
RU (1) RU2013143839A (enExample)
WO (1) WO2012118850A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
JP6097289B2 (ja) 2011-08-04 2017-03-15 アレイ バイオファーマ、インコーポレイテッド セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
KR101795562B1 (ko) * 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
HRP20180591T1 (hr) 2012-03-01 2018-05-18 Array Biopharma, Inc. Inhibitori kinaze serina ili treonina
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
RU2644947C2 (ru) 2012-08-27 2018-02-15 Аррэй Байофарма Инк. Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний
AU2013318283A1 (en) * 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
JPWO2015012328A1 (ja) * 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3077401B1 (en) 2013-12-06 2018-04-18 Genentech, Inc. Serine/threonine kinase inhibitors
MX375902B (es) 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
CA2934679C (en) * 2013-12-30 2023-02-28 Genentech, Inc. Serine/threonine kinase inhibitors
EP3443114A1 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
CN109843856B (zh) * 2016-05-18 2023-05-02 米拉蒂治疗股份有限公司 Kras g12c抑制剂
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP4273141A1 (en) 2017-09-29 2023-11-08 Mitsubishi Tanabe Pharma Corporation Optically active pyrrolidine compound and method for producing same
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2020192750A1 (zh) 2019-03-28 2020-10-01 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
MX2021011823A (es) 2019-03-29 2021-10-22 Jiangsu Hengrui Medicine Co Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
TW202110837A (zh) * 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN113825757B (zh) 2019-05-24 2023-10-20 江苏恒瑞医药股份有限公司 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
CN111170929A (zh) * 2019-12-12 2020-05-19 北京达因高科儿童药物研究院有限公司 一种由末端烯烃制备β-氨基醇的方法
ES3033417T3 (en) * 2020-09-25 2025-08-04 Janssen Pharmaceutica Nv Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitors
KR20230079120A (ko) 2020-09-29 2023-06-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 피롤로 헤테로고리계 유도체의 결정형 및 이의 제조 방법
CN115040522B (zh) * 2022-06-30 2024-02-06 牡丹江医学院 一种用于治疗肺癌的药物及其制备方法
WO2024088296A1 (zh) * 2022-10-25 2024-05-02 上海拓界生物医药科技有限公司 哌啶并嘧啶类衍生物、其制备方法及其在医药上的应用
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3
CN121969619A (zh) * 2023-10-23 2026-05-01 上海拓界生物医药科技有限公司 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
WO2025223512A1 (zh) * 2024-04-24 2025-10-30 江苏恒瑞医药股份有限公司 一种二氢吡啶并嘧啶衍生物的可药用盐、结晶形式及用途
WO2026067627A1 (zh) * 2024-09-26 2026-04-02 江苏恒瑞医药股份有限公司 一种降解剂及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
ES2262137T3 (es) 1993-10-01 2006-11-16 Novartis Ag Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
ATE293962T1 (de) 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2485166A1 (en) 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
DE602005024382D1 (de) 2004-04-13 2010-12-09 Astellas Pharma Inc Polycyclische pyrimidine als kaliumionenkanal-modulatoren
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
US20100022531A1 (en) * 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
EP1984331B1 (en) 2006-02-16 2010-10-20 Schering Corporation Pyrrolidine derivatives as erk inhibitors
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
MX2009001913A (es) 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
WO2009061761A2 (en) 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
MX2010014572A (es) 2008-06-27 2011-03-24 Novartis Ag Compuestos organicos.
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
EP2370413B1 (en) 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
JP6097289B2 (ja) 2011-08-04 2017-03-15 アレイ バイオファーマ、インコーポレイテッド セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
HRP20180591T1 (hr) 2012-03-01 2018-05-18 Array Biopharma, Inc. Inhibitori kinaze serina ili treonina
RU2644947C2 (ru) 2012-08-27 2018-02-15 Аррэй Байофарма Инк. Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний

Also Published As

Publication number Publication date
ES2543050T3 (es) 2015-08-14
EP2681215A1 (en) 2014-01-08
JP2014506930A (ja) 2014-03-20
KR20140014190A (ko) 2014-02-05
BR112013021896A2 (pt) 2016-11-08
CA2828478A1 (en) 2012-09-07
RU2013143839A (ru) 2015-04-10
EP2681215B1 (en) 2015-04-22
JP6085866B2 (ja) 2017-03-01
CN103635472B (zh) 2018-01-12
WO2012118850A1 (en) 2012-09-07
MX2013009877A (es) 2014-02-11
US9133187B2 (en) 2015-09-15
US20130338140A1 (en) 2013-12-19
MX339873B (es) 2016-06-15
CN103635472A (zh) 2014-03-12
KR101961500B1 (ko) 2019-03-22

Similar Documents

Publication Publication Date Title
CA2828478A1 (en) Serine/threonine kinase inhibitors
KR101686685B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
EP2739618B1 (en) Quinazoline compounds as serine/threonine kinase inhibitors
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
CA3230542A1 (en) Novel ras inhibitors
CA2882750A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
CN107074881B (zh) 作为nik抑制剂的新的噻吩并嘧啶衍生物
KR102889562B1 (ko) 아자-퀴놀린 화합물 및 그의 용도
JP2014502601A (ja) 置換６，６−縮合窒素複素環化合物及びその使用
CA2932729A1 (en) Serine/threonine kinase inhibitors
CA3093706A1 (en) Jak inhibitors
CN111349093B (zh) 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
WO2025148870A1 (zh) Ras抑制剂
TW202333697A (zh) Ｗｎｔ通路抑制劑化合物
CN118076613A (zh) 可用于调节AhR信号传导的化合物
HK40077297B (zh) 氮杂-喹啉化合物及其用途
WO2026037386A1 (zh) 一种具有tyk2抑制作用的化合物及其制备方法和用途
WO2019134082A1 (en) Novel pyrimidine derivatives as mth1 inhibitors
HK1199021B (en) Quinazoline compounds as serine/threonine kinase inhibitors
HK1161529B (en) Pyrazolopyrimidine jak inhibitor compounds and methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170221

MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200228